← Back to Search

Other

NTX-001 for Facial Palsy

Phase 2
Waitlist Available
Research Sponsored by Neuraptive Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up adverse events will be assessed and recorded from start of study through 48 weeks or approximately 1 year..
Awards & highlights

Study Summary

This trial is testing an investigational product called NTX-001 for safety and effectiveness in repairing nerve damage. Researchers will compare NTX-001 to the current standard of care to see if it leads to faster nerve function recovery.

Eligible Conditions
  • Facial Palsy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~adverse events will be assessed and recorded from start of study through 48 weeks or approximately 1 year..
This trial's timeline: 3 weeks for screening, Varies for treatment, and adverse events will be assessed and recorded from start of study through 48 weeks or approximately 1 year.. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events for Safety
Sunnybrook Facial Grading System
Other outcome measures
Facial Clinimetric Evaluation Scale
Image-based automatic facial landmark identification system
Intraoperative EMG
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: NTX-001Experimental Treatment1 Intervention
Solution #1, Solution #2 Active, Solution #3
Group II: Standard of CareActive Control1 Intervention
Standard neurorrhaphy

Find a Location

Who is running the clinical trial?

Neuraptive Therapeutics Inc.Lead Sponsor
3 Previous Clinical Trials
61 Total Patients Enrolled
Seth Schulman, MDStudy DirectorChief Medical Officer
1 Previous Clinical Trials
51 Total Patients Enrolled

Media Library

NTX-001 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05293522 — Phase 2
Facial Palsy Research Study Groups: NTX-001, Standard of Care
Facial Palsy Clinical Trial 2023: NTX-001 Highlights & Side Effects. Trial Name: NCT05293522 — Phase 2
NTX-001 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05293522 — Phase 2
Facial Palsy Patient Testimony for trial: Trial Name: NCT05293522 — Phase 2
~1 spots leftby May 2025